Exelixis, Inc. (EXEL) Covered Calls

Exelixis, Inc. is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. The company flagship product, cabozantinib, is a multi-kinase inhibitor approved for various indications including renal cell carcinoma and hepatocellular carcinoma. Exelixis is also advancing a robust pipeline of small molecules and biotherapeutics, such as zanzalintinib, to address significant unmet needs in oncology.

You can sell covered calls on Exelixis, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for EXEL (prices last updated Thu 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Exelixis, Inc. is a globally ambitious oncology company at the forefront of innovating next-generation medicines. By leveraging its deep expertise in drug discovery and development, the firm has established a strong commercial foundation centered on its lead molecule, cabozantinib. The company strategy focuses on expanding the reach of its current products while rapidly evolving its portfolio to target a broader range of tumor types through internal innovation and strategic partnerships.

Core Business and Products

The company primary revenue driver is the cabozantinib franchise, marketed as CABOMETYX and COMETRIQ. These therapies are potent inhibitors of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which are critical to cancer cell growth and survival. CABOMETYX is a market leader in renal cell carcinoma (RCC) and has seen significant uptake in neuroendocrine tumors (NET) following recent regulatory expansions, providing a stable and growing cash flow to fund future research.

Beyond its lead molecule, the firm is developing zanzalintinib (formerly XL092), an optimized next-generation TKI designed to improve upon the pharmacokinetic profile of cabozantinib. The company is aggressively moving zanzalintinib through pivotal trials, including the STELLAR program, for indications such as colorectal and kidney cancers. Additionally, the firm is expanding into new modalities including antibody-drug conjugates (ADCs) and bispecific antibodies, aiming to create a diversified oncology powerhouse.

Competitive Landscape

The oncology market is characterized by intense competition from global pharmaceutical giants and specialized biotech firms. The company competes based on the clinical differentiation of its multi-kinase inhibitors and its ability to execute complex combination trials. Key competitors that are publicly traded on major exchanges and feature active, tradeable options include:

1. Bristol-Myers Squibb Co: A major partner and competitor in the renal cell carcinoma space, particularly with its immunotherapy combinations.
2. Pfizer Inc: A leader in the oncology market with competing TKI therapies for kidney and other solid tumors.
3. Merck & Co Inc: Its flagship immunotherapy, Keytruda, is frequently used both in combination and in competition with the company therapies.
4. Incyte Corp: A biopharmaceutical company focused on oncology and inflammation that competes for market share in specialized cancer indications.
5. Vertex Pharmaceuticals: While focused on different disease areas, it represents a peer in the large-cap biotech space competing for institutional investment.

Strategic Outlook and Innovation

The strategic focus of the firm is centered on achieving "terminal velocity" for its cabozantinib franchise while transitioning to its next generation of assets. By 2026, the company expects to reach significant regulatory milestones for zanzalintinib, potentially establishing it as a second commercial franchise. This "AI-enabled" and data-driven approach to drug development is intended to shorten clinical timelines and increase the probability of success for its early-stage pipeline assets.

Furthermore, the firm maintains a disciplined capital allocation strategy, utilizing its strong balance sheet to fund aggressive stock buybacks and strategic business development. By acquiring or partnering on high-impact opportunities that align with its "Cabo lens"—prioritizing molecules with the potential to become new standards of care—Exelixis aims to sustain long-term growth. The ultimate goal is to evolve from a single-product company into a diversified leader in precision oncology, providing life-extending treatments to more patients worldwide.

Want more examples? EXE Covered Calls | EXI Covered Calls